Enviado em

GrowGeneration Shares Slide After Revenue Miss Overshadows Margin Gains

Cannabis equities opened Thursday on soft footing, with the sector's two main exchange-traded funds easing fractionally even as individual tickers moved sharply in both directions. The AdvisorShares Pure US Cannabis ETF (MSOS) sat at $4.08, down 0.5%, while the Amplify Seymour Cannabis ETF (CNBS) traded at $23.48, off 0.3%. Those modest ETF moves hide a messier picture underneath: of the 35 tickers tracked, 22 traded below their previous close, and the session's biggest story belonged to a hydroponics supplier that beat on profitability but missed on the top line.

GrowGeneration's Margin Story Gets Lost in a Revenue Miss

GrowGeneration (GRWG) fell 16.6% to $1.26 after third-quarter results landed Monday evening. Net sales came in at $44.8m, down from $47.3m a year earlier and short of the $46.35m analysts had penciled in, according to Investing.com. Here's the catch, though: the headline miss obscures a genuinely improved operating picture. Gross margin climbed 520 basis points to 32.4%, adjusted EBITDA reached $2.3m, and the company posted positive GAAP net income. It also closed the quarter with $41.8m in cash and zero debt - not a balance sheet in distress, by any measure.

What's striking here is the market's verdict: investors punished the revenue shortfall far more than they rewarded the margin expansion. That reaction tracks a broader pattern in cannabis retail and ancillary supply, where thin trading volumes and small floats amplify any disappointment. GrowGeneration has been steering its business away from brick-and-mortar hydroponics stores toward commercial cultivation customers, a shift that can mean lumpier quarterly revenue even as unit economics improve. For wholesalers and suppliers watching the ancillary space, the lesson is familiar: a cleaner balance sheet does not guarantee a calm stock chart.

Turning Point Brands and Tilray Show Diverging Pressure Points

Turning Point Brands (TPB) dropped to $58.81, roughly $4 below its prior close, after Needham trimmed its price target from $125 to $95 while keeping a buy rating, per MarketBeat. That downgrade in target price came just two days after the company posted earnings per share of $0.35 and revenue of $151.1m - both ahead of estimates, according to GuruFocus. A price-target cut following a beat sounds contradictory on paper, but in practice analysts often reset valuations after a run-up, even when the underlying quarter looks solid.

Tilray Brands (TLRY) offered a different flavor of pressure. Shares slipped another 1.5% to $2.61, extending a slide that GuruFocus pegged at more than 20% over the past month, including a roughly 7% drop on Tuesday alone. The through-line for Tilray isn't a single bad print; it's accumulated investor skepticism about the path to sustained profitability, a concern that shows up repeatedly across multi-state operators and Canadian producers still working through excess cultivation capacity and thin wholesale pricing.

Canopy Growth's Quiet Gain and the Limits of Daily Price-Watching

Canopy Growth (CGC) edged up 2.1% to $0.605, a move with no clear same-day trigger. Its fiscal second-quarter results, released November 6, showed net revenue up 22%, driven by a 141% jump in international cannabis sales alongside 18% growth in Canadian medical and 17% in Canadian adult-use. The company has pointed to a strengthened EU GMP supply chain as the backbone for further international expansion - a compliance-heavy undertaking, since EU Good Manufacturing Practice certification requires rigorous batch tracking, lab testing, and documentation standards well beyond what most domestic markets demand.

Glass House Brands' OTC line (GLASF) dropped 12.4% to $2.26, though that figure deserves a caveat: OTC quotes often lag a full trading day, and the company's primary listing has since moved to the NYSE under the ticker GLAS. Its preliminary third-quarter numbers showed revenue climbing to $56.8m from $47.0m the prior quarter, even as average selling price per pound fell to $150 from $211 - a reminder that wholesale cannabis pricing continues to compress in mature markets, squeezing cultivators regardless of volume gains.

What the Broader Tape Signals for Operators

Among multi-state operators, the moves were comparatively tame: Green Thumb Industries (GTBIF) held near $6.58, Curaleaf (CURLF) slipped 0.7% to $8.87, and Cronos Group (CRON) gained 1.2% to $3.45. Ancillary names with indirect cannabis exposure - Altria, Jazz Pharmaceuticals, Innovative Industrial Properties, and cannabis lender AFC Gamma - traded in a narrower band, a pattern typical when the plant-touching side of the sector absorbs earnings-driven volatility while diversified or lending-exposed names stay comparatively steady.

For dispensary operators and suppliers tracking these tickers, the session underscores a persistent dynamic: public cannabis equities remain thinly traded and highly sensitive to single-quarter results, making them an imperfect proxy for underlying retail demand. Regular US trading opens at 14:30 GMT.